From:
To:
Cc:

Subject: FW: Monash IVF Non-invasive preimplantation genetic testing for an euploidy [SEC=OFFICIAL]

Date: Monday, 18 January 2021 11:25:56 AM

Attachments: image004.png

image005.png image006.png

Dear

As requested in the team leader meeting.

Departmental Officer
Devices Post Market Monitoring Section
Medical Devices Surveillance Branch

Phone: Email:

Therapeutic Goods Administration Department of Health PO Box 100 Woden ACT 2606 www.tga.gov.au



Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission.

From:

Sent: Wednesday, 13 January 2021 5:24 PM

To: Cc:

Subject: RE: Monash IVF Non-invasive preimplantation genetic testing for aneuploidy [SEC=OFFICIAL]

REMINDER: Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

D21-2051148

Hi

Thanks very much for confirming you received letter.

That would be great if you could forward the outcome of your investigation into Monash IVF's non-invasive preimplantation genetic testing for aneuploidy once completed. Please do not hesitate to contact me if you require any information from Kind Regards, Sent: Wednesday, 13 January 2021 3:57 PM To: Cc: Subject: Monash IVF Non-invasive preimplantation genetic testing for aneuploidy [SEC=OFFICIAL] D21-2049026 Dear I am writing to acknowledge receipt of letter dated 5 January 2021 regarding the suspensions of Monash IVF's non-invasive preimplantation genetic testing for aneuploidy. I understand you will be progressing the investigation once requested I provide any information to you. In regard to request, we will advise of the outcome of our investigation once it is complete, including a summary of the findings. If you have any questions please feel free to contact me.

Kind regards,

Devices Post Market Monitoring Section Medical Devices Surveillance Branch



Therapeutic Goods Administration Department of Health PO Box 100 Woden ACT 2606 www.tga.gov.au

For ongoing information and updates please subscribe to the TGA's <u>Medical Devices Information</u> and <u>IVDs Information</u> email subscription services.

This response is general information given to you without prejudice; it is not binding on the TGA and you should get your own independent legal advice to ensure that all of the legislative requirements are met.

Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

Message protected by MailGuard: e-mail anti-virus, anti-spam and content filtering. http://www.mailguard.com.au

Report this message as spam